Page 22 - Pharma Industry

Weak Q3 show, margin pressures to keep Sanofi stock under pressure

Growth led by power brands and new launches could recover as pandemic impact wanes

PLI scheme: Pharma industry expects more guidelines on investment

B R Sikri, chairman of the Federation of Pharma Entrepreneurs, said, higher incentives would have meant more production of cancer drugs, thereby, bringing down their prices

Centre announces Rs 15,000 crore PLI for pharma, IT hardware sectors

Pharma scheme aims at Rs 3 trillion incremental sales, 100,000 jobs; experts say hardware scheme to help India become electronics manufacturing hub for the world

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Govt has decided to shut 2 pharma PSUs, disinvest other 3: Govt tells LS

The government has decided to close two pharma public sector undertakings and disinvest the other three, Parliament was informed on Tuesday. "The Department of Pharmaceuticals has five public sector undertakings (PSUs). Out of the five PSUs, the government has taken a decision to close two pharma PSUs, namely Indian Drugs & Pharmaceuticals Ltd (IDPL) and Rajasthan Drugs & Pharmaceuticals Ltd (RDPL)," Minister ofChemicals and Fertilisers D V Sadananda Gowda said in response to a question in the Lok Sabha. The government has also decided to strategically disinvestthe other three -- Hindustan Antibiotics Ltd (HAL), Bengal Chemicals & Pharmaceuticals Ltd (BCPL), and Karnataka Antibiotics & Pharmaceutical Ltd (KAPL), he added. The government has offered voluntary retirement benefits to allemployees of IDPL and RDPL, Gowda said. "However, the Committeeof Ministers constituted on September 9, 2019, will take necessary decisions pertaining toclosure/strategic sale of the ...

PE firm Advent International acquires 51% stake in ZCL Chemicals

ZCL is one of the fastest-growing manufacturers of specialty active pharmaceutical ingredients (APIs) and advanced intermediates

Indian pharma market expected to hit $130 billion by 2030: Sadananda Gowda

The Indian pharmaceutical industry has proved to be a dependable supplier of quality drugs in a time of global need on account of the COVID-19 pandemic, and is expected to reach a size of USD 130 billion by 2030,Chemical and Fertiliser Minister D V Sadananda Gowda said on Monday. Following the onset of the pandemic, the Indian pharma industry has shown its role as a reliable supplier of drugs and medical devices in a time of need,he added. "The total market size of the Indian pharma industry is expected to reach USD 130 billion by 2030. The medical devices industry in India has the potential to grow at 28 per cent per annum to reach USD 50 billion by 2025," Gowda said. He wasaddressingthe curtain raiser press conference on the 6th edition of 'Indian Pharma & India Medical Device 2021'. "India has been serving more than 200 countries with its pharma products and will continue to discharge its responsibilities. We intend tocontinue formulating plans that are based on sound science, .

KKR-backed JB Chemicals scouts for acquisitions, plans to revamp business

With the former Cipla head at the helm, JB Chemicals now plans to diversify into paediatrics and respiratory

Pharmaceutical exports jumped 12.43% during April-December 2021

The exports grew to $17.57 billion, Parliament was informed on Friday

Jazz Pharma to buy GW Pharmaceuticals in a $7.2 billion cash-and-stock deal

GW Pharma's Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year

PI Industries: Reaping gains from sustained growth across businesses

Strong beat in Q3, positive management commentary sees stock gain more than 9 per cent on Wednesday

Indegene's valuation reaches $700 mn; raises $200 mn from Carlyle, Brighton

Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the funds to accelerate its M&A (merger and acquisition) and global expansion plans

Pharma to real estate, here's look at the winners and losers amid Covid-19

While several sectors like airlines and real estate are still reeling from the pandemic, here's is look at the winners and losers during the period

Sun Pharma Q3 PAT doubles to Rs 1,852 cr, rides on record quarterly revenue

The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval

Eris Lifesciences Q3 net up 42% to Rs 90 cr, total income rises by 14%

Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients

Pharma industry has risen to occasion during the pandemic: Satish Reddy

He said the crisis itself presented the industry with several opportunities and allowed us to think differently

Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities

Govts or manufacturers, who is on the hook if Covid-19 vaccines go wrong?

Policy makers in developing nations may not have a choice but to take what they can get - easily, cheaply and quickly

Sun Pharma starts phase 2 trial for drug to treat plaque psoriasis

Sun Pharma on Monday said it has initiated Phase 2 clinical trial for a product being developed to treat patients with moderate to severe plaque psoriasis.

Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey